FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first…
18 Sep 2026
Novo targets oral macrocycles with $1.4bn Orbis partnership
Novo has teamed up with macrocycle specialist Orbis Medicines in a deal worth up to $1.4bn, marking an effort by the Danish pharma to bolster its cardiometabolic pipeline after a…
18 Sep 2026
Ona Therapeutics to develop ADC with WuXi’s payload-linker platform
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC)…
18 Sep 2026
Roche agrees to $1bn deal with Dualitas for bispecific antibody research
Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up to $1bn, aiming to discover and develop bispecific antibodies for…
17 Sep 2026
Novo taps Anthropic’s Claude to ‘supercharge’ R&D efforts
Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the frontier of pharmaceutical innovation. The…
17 Sep 2026
Cellares and GenomeFrontier to assess automated GF-CART01 production
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform. The collaboration, which marks Cellares’…
17 Sep 2026
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive sleep apnoea syndrome (OSAS) and for narcolepsy types 1 and…